Subgroups, prognosis and treatment in breast cancer

Alex Pratt, oncologist at Clinique and president of the Idibaps group.

The advanced metastatic breast cancer It represents a disease fatal Today and your date classification does not always reflect reality of patients. Use genomics To delve deeper into your Category is the path from a research project to five years led display Alex Prattoncologist at Clinique and group leader Idibabs. Within these tumors, which are believed to be pre-existing sensitive hormonegenomics dictates the opposite: “Part of this 70 percent Of the tumors, 20-30 percent, are already violent s Not sensitive to hormones. From here, we started a project aimed at discovering new ways to diagnose positive breast cancer hormoneas well as new treatments,” explains an oncologist at medical writing.

Better understanding and understanding Tumor molecular subtype It’s one of the answers the research team hopes to discover over the five years that the project runs. Although the way to identify him is known today, Pratt goes further: “We must understand it heterogeneityDNA level, immune system, etc. We treat the HER2 enriched pool as if it were a swimming pool, but there subgroups We have to call them. We have agreements with other hospitals such as Val Debronne or the October 12And we hope to get there thousand samples“.


“There are subgroups within HER2 and we have to call them names.”


Thanks to an academic scholarship from Kris Foundationwhich seeks to promote the development of clinical programs with the potential to achieve a real impact in the treatment of patients, the project, which will last a total of five years, has been marked as a first step. Distinguish the patient’s biology. “We want to understand the biological characteristics that a tumor has in order to create a genome atlas of this molecular subtype,” the oncologist explains.

Another goal that the Clínic researchers hope to achieve during the life of the project is to Learn about treatments that may work with this group of cancer patients. “We have already developed models in the lab preclinical in tumors the mouse We test the treatments that are used ChemotherapyDifferent AntibodiesAnd the Immunotherapy, etc. In these five years, we hope to find a combination of treatments to design and test patients for a study,” Pratt details.

Blood, a possible way to identify breast cancer

Recognizing this group of patients is not easy today, because it is necessary to turn to it Metastasis biopsy Already genomic analyses. The the blood It is, for Prat, “a method we are trying to promote to define this subtype in a file less invasive. There are many metastases and biopsies can be risky. In addition, the tissue we get from the tumor is very small We can’t do genomics. We have to find alternative ways, to do faster studies.”


“Blood can help us identify this subtype of cancer in a less invasive way”


Under immunotherapy, the group led by Pratt currently does not close any doors and is open to all kinds of treatments. “So far we’ve managed to do that Two proofs of concept In groups of young patients, testing classic immunotherapy s HER2 . receptor inhibition in a small molecule. From now on, we will continue to test different treatments,” emphasizes the oncologist at Clinique.

Trastuzumab, a potential treatment in the future

Posted last Sunday in New England Journal of Medicine Phase III clinical trial in metastatic breast cancer led by Javier Cortes, director of the International Breast Cancer Center (Ibcc), which Pratt also participated in. Researchers have demonstrated the efficacy of a new drug for metastatic breast cancer with low expression of HER2. trastuzumab deroxtecan. In addition, experts have shown that of all patients, “the median Survive free progress It was 9.9 months In the group trastuzumab deruxtecan and 5.1 month in the selection group medicalThe overall survival rate was 23.4 months and 16.8 months, respectively.

Regarding this aspect, Pratt does not rule out that this research will become a “potential treatment for positive breast cancer hormone In the future. Thanks to this new drug that brings together 7-8 particles From very potent chemotherapy with the trastuzumab antibody, patients’ survival is prolonged.”

Although it may contain statements, statements, or notes from health institutions or professionals, the information in medical writing is edited and prepared by journalists. We recommend the reader to consult a health professional for any health-related questions.

Leave a Comment